Regenacip 200MIU Injection

Regenacip 200MIU Injection contains mesenchymal stromal cells derived from the bone marrow of unrelated healthy adult donors. It is indicated for the treatment of critical limb ischemia caused by atherosclerotic peripheral artery disease, a condition in which blood vessels supplying the legs become narrowed due to fat deposits, resulting in insufficient blood supply to maintain normal limb function. Critical limb ischemia develops when blood flow to the limb is inadequate to meet the metabolic demands of limb cells, even during rest. Regenacip 200MIU Injection is not recommended for use in adolescents and children under 18 years of age. Effective contraception should be used during treatment. Prior to initiating this medication, inform your physician if you have allergies to porcine or bovine products or if you have any other medical conditions.

Treats critical limb ischemia due to atherosclerotic peripheral artery disease (PAD)

Regenacip 200MIU Injection can help develop new blood vessel cells and improve blood supply to the affected limb or its parts.

Regenacip 200MIU Injection is given only in a hospital set up by a trained healthcare provider. It will be given to you as an injection into your muscle (intramuscularly) for adults in the arm and children in the thigh. Your doctor will decide your most apt dosage based on age, body weight, and physical circumstances.

Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them. Common: Fever Nausea, vomiting Pain and infection at the injection site

Maintain a comprehensive record of your symptoms, side effects, and any changes in your health throughout the Regenacip 200MIU Injection treatment. This information can significantly assist your healthcare team in tailoring the treatment plan to suit your specific needs. Stay well-hydrated, engage in light physical activities as advised, and prioritize a balanced diet to support the overall effectiveness of the therapy.